Information Provided By:
Fly News Breaks for September 12, 2016
NVO
Sep 12, 2016 | 05:53 EDT
Deutsche Bank analyst Tim Race upgraded Novo Nordisk to Buy saying the company's long-term prospects in diabetes are positive. Insulin price concerns in the U.S. are well known and reflected by the company's 24% share price decline year-to-date, Race tells investors in a research note. He has a DKK 360 price target for the shares.
News For NVO From the Last 2 Days
NVO
Mar 26, 2024 | 07:08 EDT
JPMorgan estimates Amgen (AMGN) without its obesity pipeline is worth $240-$250 per share and that the market is assigning $30-$40 per share of value to Maritide. While the competitive bar for Maritide is high and moving higher based on Novo Nordisk's (NVO) recent pipeline updates, the obesity market is also "unprecedented in terms of size," the analyst tells investors in a research note. The firm estimates peak sales for Maritide of $6B, equating to mid-single-digit share within the incretin space. JPMorgan believes this supports a value roughly in-line with what is reflected in Amgen's current share price. It sees a positive risk/reward scenario given the recent pullback but maintains a Neutral rating on the name with a $290 price target. The firm says Amgen is viewed as the best positioned name beyond Eli Lilly (LLY) and Novo to have a role in the obesity space.